Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Professor John Lunec.

Newcastle AuthorsTitleYearFull text
Maryam Zanjirband Zanjirband
Professor Nicola Curtin
Professor John Lunec
Erratum: Correction: Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer (Oncotarget (2017) 8 41 (69779-69796))2024
Erhan Aptullahoglu
Dr Jonathan Wallis
Dr Helen Marr
Dr Elaine Willmore
Professor John Lunec
et al.
SF3B1 Mutations Are Associated with Resistance to Non-Genotoxic MDM2 Inhibition in Chronic Lymphocytic Leukemia2023
Bassier Zadran
Daniel Wainwright
Dr Yvonne Bury
Dr Saimir Luli
Rachel Howarth
et al.
Impact of retrotransposon protein L1 ORF1p expression on oncogenic pathways in hepatocellular carcinoma: the role of cytoplasmic PIN1 upregulation2023
Dr Carmela Ciardullo
Dr Jonathan Wallis
Dr Helen Marr
Dr Nicholas Bown
Dr Elaine Willmore
et al.
Splicing Modulation Results in Aberrant Isoforms and Protein Products of p53 Pathway Genes and the Sensitization of B Cells to Non-Genotoxic MDM2 Inhibition2023
Dr Hayden Bell
Dr Helen Blair
Mankaran Singh
Professor Anthony Moorman
Professor Olaf Heidenreich
et al.
Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia2023
Professor John Lunec
p53 as a biomarker and potential target in gastrointestinal stromal tumors2022
Victoria Chamberlain
Dr Yvette Drew
Professor John Lunec
Tipping growth inhibition into apoptosis by combining treatment with MDM2 and WIP1 inhibitors in p53WT uterine leiomyosarcoma2022
Dr Corey Chan
Dr Emma Haagensen
Dr Hayeit Tensaout
Dr Kate Rennie
Dr Zakareya Gamie
et al.
Co‑localisation of intra‑nuclear membrane type‑1 matrix metalloproteinase and hypoxia inducible factor‑2α in osteosarcoma and prostate carcinoma cells2021
Dr Praveen Dhondurao Sudhindar
Daniel Wainwright
Dr Santu Saha
Rachel Howarth
Misti McCain
et al.
HCV Activates Somatic L1 Retrotransposition—A Potential Hepatocarcinogenesis Pathway2021
Marco Zaki
Dr Ahmed Mahdi
Dr Gillian Patman
Anna Whitehead
Joao Mauricio
et al.
Key features of the environment promoting liver cancer in the absence of cirrhosis2021
Dr Ian Hardcastle
Dr Ruth Bawn
Dr Tim Blackburn
Dr Celine Cano
Dr Sarah Cully
et al.
Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein–Protein Interaction2021
Professor John Lunec
WIP1 inhibition by GSK2830371 potentiates HDM201 through enhanced p53 phosphorylation and activation in liver adenocarcinoma cells2021
Dr Nicholas Bown
Professor John Lunec
Professor Deborah Tweddle
Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group2020
Professor John Lunec
Pattern of nucleotide variants of TP53 and their correlation with the expression of p53 and its downstream proteins in a Sri Lankan cohort of breast and colorectal cancer patients2020
Professor John Lunec
Targeting P53 as a future strategy to overcome gemcitabine resistance in biliary tract cancers2020
Dr Chiao-En Wu
Tsin Koay
Professor Penny Lovat
Professor John Lunec
TP53 mutant cell lines selected for resistance to MDM2 inhibitors retain growth inhibition by MAPK pathway inhibitors but a reduced apoptotic response2019
Dr Chiao-En Wu
Tsin Koay
Arman Esfandiari
Professor Penny Lovat
Professor John Lunec
et al.
ATM Dependent DUSP6 Modulation of p53 Involved in Synergistic Targeting of MAPK and p53 Pathways with Trametinib and MDM2 Inhibitors in Cutaneous Melanoma2019
Dr Carmela Ciardullo
Erhan Aptullahoglu
Dr Laura Woodhouse
Dr Wei-Yu Lin
Dr Jonathan Wallis
et al.
Non-genotoxic MDM2 inhibition selectively induces pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells2019
Vahinipriya Manoharan
Professor John Lunec
Nucleotide variants and protein expression of TP53 in a Sri Lankan cohort of patients with head and neck cancer2019
Dr Lindi Chen
Philip Berry
Dr Jennifer Bonner
Calum Kirk
Dr Katrina Wood
et al.
Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma2019
Dr Yan Zhao
Professor John Lunec
A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage2018
Honorine Lebraud
Dr Richard Noble
Nicole Phillips
Dr Yan Zhao
Professor Herbie Newell
et al.
A highly potent clickable probe for cellular imaging of MDM2 and assessing dynamic responses to MDM2-p53 inhibition2018
Dr Lindi Chen
Arman Esfandiari
Professor John Lunec
Professor Deborah Tweddle
Characterisation of the p53 pathway in cell lines established from TH-MYCN transgenic mouse tumours2018
Lucy Gentles
Liz Matheson
Dr Nicholas Bown
Alice Bradbury
Maryam Zanjirband Zanjirband
et al.
Characterization and drug sensitivity of a novel human overian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor2018
Abdullah Malik
Dr Jeffry Hogg
Professor John Lunec
Professor Derek Manas
Jeremy French
et al.
External validation of nomograms for prediction of survival outcome in retroperitoneal sarcoma using the North East England cohort2018
Arman Esfandiari
Nan Wang
Dr Ahmed Mahdi
Erhan Aptullahoglu
Professor Penny Lovat
et al.
Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeuticstrategy in cutaneous melanoma2018
Maryam Zanjirband Zanjirband
Professor Nicola Curtin
Professor John Lunec
Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer2017
Dr Aiste McCormick
Gavin Cuthbert
Dr Rachel O'Donnell
Dr Brian Wilson
Huw Thomas
et al.
Functional characterisation of a novel ovarian cancer cell line, NUOC-12017
Dr Lindi Chen
Philip Berry
Dr Jennifer Bonner
Dr Katrina Wood
Professor Gareth Veal
et al.
In vivo evaluation of the intravenous MDM2-p53 antagonist RO6839921 alone and in combination with temozolomide in TP53 wild-type orthotopic models of neuroblastoma2017
Dr Catherine Drummond
Arman Esfandiari
Dr Xiaohong Lu
Dr Claire Hutton
Dr Jennifer Jackson
et al.
TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation2016
Arman Esfandiari
Dr Sirintra Nakjang
Professor John Lunec
Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner2016
Dr Ioannis Kotsopoulos
Dr Asima Mukhopadhyay
Professor John Lunec
Professor Nicola Curtin
Ali Kucukmetin
et al.
IN VITRO SINGLE AGENT RUCAPARIB CYTOTOXICITY AND CISPLATIN CHEMO-POTENTIATION IN CERVICAL CANCER CELL LINES2016
Dr Ian Logan
Dr Urszula McClurg
Dr Dominic Jones
Daniel O'Neill
Dr Fadhel Shaheen
et al.
Nutlin-3 inhibits androgen receptor-driven c-FLIP expression, resulting in apoptosis of prostate cancer cells2016
Dr Ioannis Kotsopoulos
Ali Kucukmetin
Dr Asima Mukhopadhyay
Professor John Lunec
Professor Nicola Curtin
et al.
Poly(ADP-Ribose) Polymerase in Cervical Cancer Pathogenesis Mechanism and Potential Role for PARP Inhibitors2016
Maryam Zanjirband Zanjirband
Professor Richard Edmondson
Professor John Lunec
Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents in combined treatment with cisplatin in ovarian cancer2016
Dr Jeffry Hogg
Professor Derek Manas
Dr Daniela Lee
Dr Petra Dildey
Professor John Lunec
et al.
Surgical outcome and patterns of recurrence for retroperitoneal sarcoma at a single centre.2016
Dr Laura Woodhouse
Clark Crawford
Dr Scott Marshall
Dr Nicholas Bown
Dr Elaine Willmore
et al.
Assessment and targeting of the MDM2-p53 network in CLL2015
Dr Arman Esfandiari
Professor Nicola Curtin
Professor John Lunec
Chemical inhibition or transient knockdown of wild-type p53 induced phosphatase 1 (WIP1/PPM1D) potentiates the response to MDM2 inhibitors in a p53-dependent manner2015
Dr Nicholas Bown
Professor John Lunec
Professor Deborah Tweddle
Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification2015
Dr Ashleigh Herriott
Dr Susan Tudhope
Gesa Junge
Natalie Rodrigues
Dr Miranda Patterson
et al.
PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in Chronic Lymphocytic Leukaemia2015
Professor Ruth Plummer
Dr Jane Margetts
Professor John Lunec
Dr Joyce Nutt
Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker2015
Dr Lindi Chen
Professor Herbie Newell
Professor John Lunec
Professor Deborah Tweddle
Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma2015
Dr Andrey Zaytsev
Dr Barry Dodd
Emeritus Professor Bernard Golding
Professor Roger Griffin
Dr Xiaohong Lu
et al.
Searching for Dual Inhibitors of the MDM2-p53 and MDMX-p53 Protein-Protein Interaction by a Scaffold-Hopping Approach2015
Alex Liu
Dr Catherine Drummond
Professor Jane Endicott
Emeritus Professor Bernard Golding
Professor Roger Griffin
et al.
An X-ray crystal structure-based understanding of the inhibition of the MDM2-p53 protein-protein interaction by isoindolinones2014
Dr Emma Bell
Dr Frida Ponthan
Claire Whitworth
Professor Deborah Tweddle
Professor John Lunec
et al.
COX2 expression in neuroblastoma increases tumorigenicity but does not affect cell death in response to the COX2 inhibitor celecoxib2014
Dr Jeffry Hogg
Jeremy French
Professor John Lunec
Nutlin-3 is cytotoxic in TP53 WT liposarcoma and leiomyosarcoma in vitro and can act both synergistically and antagonistically with ionising radiation2014
Dr Susan Tudhope
Dr Yan Zhao
Dr Anita Wittner
Annalisa Bertoli
Santosh Adhikari
et al.
Profiling inhibitors of MDM2: p53 and MDMX: p53 in relation to MDMX protein levels2014
Dr Lindi Chen
Dr Yan Zhao
Dr Gail Halliday
Philip Berry
Professor Herbie Newell
et al.
Structurally diverse MDM2-p53 antagonists act as modulators of MDR-1 function in neuroblastoma2014
Professor John Lunec
The clinical development of p53-reactivating drugs in sarcomas - charting future therapeutic approaches and understanding the clinical molecular toxicology of Nutlins2014
Annalisa Bertoli
Santosh Adhikari
Dr Suzannah Harnor
Dr Yan Zhao
Professor John Lunec
et al.
Validation studies with small-molecule modulators of the MDM2/MDMX-p53 binding interaction2014
Dr Tim Blackburn
Christopher Coxon
Dr Xiaohong Lu
Emeritus Professor Bernard Golding
Professor Roger Griffin
et al.
Diaryl- and triaryl-pyrrole derivatives: inhibitors of the MDM2-p53 and MDMX-p53 protein-protein interactions2013
Nidal Boulos
Dr Michael Tilby
Professor Deborah Tweddle
Professor John Lunec
Identification and characterisation of STMN4 and ROBO2 gene involvement in neuroblastoma cell differentiation2013
Sarah Cully
Dr Celine Cano
Emeritus Professor Bernard Golding
Professor Roger Griffin
Professor John Lunec
et al.
Regiospecific synthesis of isoindolinones as MDM2 inhibitors2013
Professor Deborah Tweddle
Professor John Lunec
MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-632012
Dr Swethajit Biswas
Professor John Lunec
Professor Kim Bartlett
Non-glucose metabolism in cancer cells—is it all in the fat?2012
Dr Kenneth Rankin
Professor John Lunec
Craig Gerrand
Dr Swethajit Biswas
Of Dogs and Men: Comparative Biology as a Tool for the Discovery of Novel Biomarkers and Drug Development Targets in osteosarcoma2012
Dr Christine Challen
Dr John Anderson
Professor Zofia Chrzanowska-Lightowlers
Professor Robert Lightowlers
Professor John Lunec
et al.
Recombinant human MDM2 oncoprotein shows sequence composition selectivity for binding to both RNA and DNA2012
Dr Swethajit Biswas
Dr Kenneth Rankin
Anna Long
Dr Jennifer Jackson
Dr Mark Birch
et al.
The prognostic role of MT1-MMP and HIF Isoforms in Human Osteosarcoma2012
Dr Nicholas Bown
Professor John Lunec
Professor Deborah Tweddle
A Multilocus Technique for Risk Evaluation of Patients with Neuroblastoma2011
Dr Ian Hardcastle
Alex Liu
Dr Eric Valeur
Anna Watson
Shafiq Ahmed
et al.
Isoindolinone Inhibitors of the Murine Double Minute 2 (MDM2)-p53 Protein-Protein Interaction: Structure-Activity Studies Leading to Improved Potency2011
Dr Karim Bennaceur
Dr Catherine Drummond
Professor Jane Endicott
Emeritus Professor Bernard Golding
Professor Roger Griffin
et al.
MDM2-p53 protein-protein interaction inhibitors: A-ring substituted isoindolinones2011
Dr Jane Carr-Wilkinson
Bojidar Goranov
Dr Chris Redfern
Dr Laura Gamble
Professor John Lunec
et al.
Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expression2011
Dr Joyce Nutt
Kieran O'Toole
Dr Fiona Black
Mike Cole
Professor Ruth Plummer
et al.
Expression of methylthioadenosine phosphorylase (MTAP) in malignant pleural mesothelioma (MPM) and its implication for pemetrexed-based chemotherapy2010
Dr Jane Carr-Wilkinson
Kieran O'Toole
Angela Baker
Julian Board
Mike Cole
et al.
High frequency of p53/MDM2/p14ARF pathway abnormalities in relapsed neuroblastoma2010
Dr Emma Bell
Dr Lindi Chen
Professor John Lunec
Professor Deborah Tweddle
MYCN oncoprotein targets and their therapeutic potential2010
Dr Lindi Chen
Dr Laura Gamble
Professor John Lunec
Professor Deborah Tweddle
p53 is a direct transcriptional target of MYCN in neuroblastoma2010
Dr Joyce Nutt
Kieran O'Toole
Dr Fiona Black
Amy Quinn
Professor Alan Calvert
et al.
The role of folate receptor alpha (FR alpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy2010
Amy Quinn
Professor Alan Calvert
Professor John Lunec
A Monoclonal Antibody for Detection of Folylpolyglutamate Synthetase in Paraffin Embedded Tissues2009
Dr Joyce Nutt
Kieran O'Toole
Dr Fiona Black
Professor Ruth Plummer
Professor Alan Calvert
et al.
Expression of folate receptor alpha (FRa) in malignant pleural mesothelioma patients by immunohistochemistry: a clinico-pathological analysis2009
Dr Joyce Nutt
Kieran O'Toole
Professor John Lunec
Growth inhibition by tyrosine kinase inhibitors in mesothelioma cell lines2009
Dr Ian Logan
Hesta McNeill
Susan Cook
Dr Xiaohong Lu
Professor John Lunec
et al.
Heat shock factor-1 modulates p53 activity in the transcriptional response to DNA damage2009
Dr Joyce Nutt
Professor John Lunec
The wide variation in response of mesothelioma cell lines to pemetrexed and lack of relationship to presence of folate receptor alpha (Fra)2009
Dr Xiaohong Lu
Professor John Lunec
Disruption of the MYC transcriptional function by a small-molecule antagonist of MYC/MAX dimerization2008
Dr Katrina Wood
Dr Michael Jackson
Dr Maria Lastowska
Dr Darroch Hall
Dr Helen Imrie
et al.
Histological profile of tumours from MYCN transgenic mice2008
Dr Xiaomei Lu
Alex Liu
Dr Ian Hardcastle
Professor Roger Griffin
Emeritus Professor Bernard Golding
et al.
MDM2 and MDMX status as a determinant of in vitro cellular sensitivity to MDM2 antagonists in human tumour cell lines2008
Emeritus Professor Bernard Golding
Professor Roger Griffin
Dr Claire Hutton
Professor John Lunec
Professor Herbie Newell
et al.
MEDI 147-Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction2008
Professor John Lunec
Molecular pathology and potential therapeutic targets in soft-tissue sarcoma2008
Seamus Kelly
Dr John Anderson
Dr Brian Angus
Dr Christine Challen
Professor John Lunec
et al.
The predictive value of p53 and p33ING1b in patients with Dukes'C colorectal cancer2008
Professor Alan Calvert
Professor John Lunec
A novel monoclonal antibody for detection of folate receptor alpha in paraffin-embedded tissues2007
Dr Ian Logan
Hesta McNeill
Susan Cook
Dr Xiaohong Lu
Professor John Lunec
et al.
Analysis of the MDM2 antagonist nutlin-3 in human prostate cancer cells2007
Dr Emma Bell
Professor John Lunec
Professor Deborah Tweddle
Cell cycle regulation targets of MYCN identified by gene expression microarrays2007
Dr John Anderson
Professor Robert Lightowlers
Professor John Lunec
DNA and RNA Binding of a Bacterially Expressed Human MDM2 Onco-protein2007
Dr Joyce Nutt
Kilian Mellon
Professor John Lunec
hEGR1 is induced by EGF, inhibited by gefitinib in bladder cell lines and related to EGF receptor levels in bladder tumours2007
Dr Jane Carr-Wilkinson
Dr Nicholas Bown
Marian Case
Dr Andrew Hall
Professor John Lunec
et al.
High-resolution analysis of allelic imbalance in neuroblastoma cell lines by single nucleotide polymorphism arrays2007
Dr John Anderson
Dr Christine Challen
Dr Stephen Crosier
Professor John Lunec
MDM2 RNA binding is blocked by novel monoclonal antibody h-MDM2-F4-142007
Dr Lindi Chen
Professor Archibald Malcolm
Dr Katrina Wood
Mike Cole
Professor Andrew Pearson
et al.
p53 is nuclear and functional in both undifferentiated and differentiated neuroblastoma2007
Dr Jane Carr-Wilkinson
Dr Emma Bell
Professor Andrew Pearson
Professor John Lunec
Professor Deborah Tweddle
et al.
Increased frequency of aberrations in the p53/MDM2/p14ARF pathway in neuroblastoma cell lines established at relapse2006
Dr Ian Hardcastle
Dr Shafiq Ahmed
Helen Atkins
Gillian Farnie
Emeritus Professor Bernard Golding
et al.
Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold2006
Dr Emma Bell
Dr Jane Carr-Wilkinson
Dr Xiaohong Lu
Professor Penny Lovat
Professor John Lunec
et al.
The role of MYCN in the failure of MYCN amplified neuroblastoma cell lines to G1 arrest after DNA damage2006
Professor John Lunec
Characterisation of a novel p53 down-regulated promoter in intron 3 of the human MDM2 oncogene2005
Philip Keegan
Professor John Lunec
Kilian Mellon
erbB receptor expression patterns in human bladder cancer2005
Dr Ian Hardcastle
Shafiq Ahmed
Emeritus Professor Bernard Golding
Professor Roger Griffin
Dr Claire Hutton
et al.
Inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold2005
Stuart Kemp
Dr Ian Hardcastle
Dr Shafiq Ahmed
Emeritus Professor Bernard Golding
Professor Roger Griffin
et al.
Isoindolinone based inhibitors of the MDM2-p53 protein-protein interaction2005
Dr Ian Hardcastle
Dr Shafiq Ahmed
Professor Alan Calvert
Professor Nicola Curtin
Gillian Farnie
et al.
Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction2005
Professor John Lunec
Julian Board
Professor Andrew Pearson
No evidence for correlation of DDX1 gene amplification with improved survival probability in patients with MYCN-amplified neuroblastomas [15]2005
Dr Joyce Nutt
Henry Lazarowicz
Kilian Mellon
Professor John Lunec
Gefitinib ('Iressa', ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP22004
Helen Atkins
Professor John Lunec
Genomic organisation of the human MDM2 oncogene and relationship to its alternatively spliced mRNAs2004
Dr Xiaohong Lu
Professor Herbie Newell
Professor Andrew Pearson
Professor John Lunec
Identification of MYCN transcriptional activity inhibitors yields compounds which preferentially inhibit the growth of neuroblastoma cells2004
Nidal Boulos
Professor Andrew Pearson
Dr Michael Tilby
Professor John Lunec
1p deleted neuroblastoma cells differentiate following chromosome 1 reintroduction2003
Garrett Durkan
Dr Joyce Nutt
Colin Marsh
Dr Mary Robinson
Professor David Neal
et al.
Alteration in urinary matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio predicts recurrence in nonmuscle-invasive bladder cancer2003
Professor Deborah Tweddle
Julian Board
Professor Andrew Pearson
Professor John Lunec
Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[131I]iodobenzylguanidine by neuroblastoma tumors2003
Professor John Lunec
Disruption of MYC transcriptional function in cell-based reporter gene assays by small-molecule antagonists of MYC/MAX dimerization2003
Dr John Anderson
Dr Stephen Crosier
Dr Jyotsna Shrimankar
Professor John Lunec
Dr Brian Angus
et al.
Downregulation of nuclear expression of the p33ING1b inhibitor of growth protein in invasive carcinoma of the breast2003
Dr Debbie Scott
Joanna Elsden
Professor Andrew Pearson
Professor John Lunec
Genes co-amplified with MYCN in neuroblastoma: Silent passengers or co-determinants of phenotype?2003
Gillian Farnie
Dr Saeed Ahmed
Professor John Lunec
Inhibition of the MDM2-p53 interaction as a potential target in cancer therapy2003
Dr Joyce Nutt
Garrett Durkan
Kilian Mellon
Professor John Lunec
Matrix metalloproteinases (MMPs) in bladder cancer: The induction of MMP9 by epidermal growth factor and its detection in urine2003
Dr Nicholas Bown
Julie Freeman-Edward
Professor John Lunec
Dr Katia Mazzocco
Steven O'Neill
et al.
Quality assessment of genetic markers used for therapy stratification2003
Dr Jane Carr-Wilkinson
Julian Board
Dr Katrina Wood
Professor Andrew Pearson
Professor John Lunec
et al.
Selection for p53 mutant cells by chemotherapy in high-risk neuroblastoma2003
Dr Xiaohong Lu
Professor Andrew Pearson
Professor John Lunec
The MYCN oncoprotein as a drug development target2003
Dr Debbie Scott
Julian Board
Dr Xiaohong Lu
Professor Andrew Pearson
Dr Rebecca Kenyon
et al.
The neuroblastoma amplified gene, NAG: Genomic structure and characterisation of the 7.3 kb transcript predominantly expressed in neuroblastoma2003
Professor Deborah Tweddle
Professor Andrew Pearson
Professor John Lunec
The p53 pathway and its inactivation in neuroblastoma2003
Dr John Anderson
Professor John Lunec
Dr Brian Angus
The role of the tumour suppressor p33ING1b in human neoplasia2003
Dr Maria Lastowska
Simon Cotterill
Natalie Bown
Professor John Lunec
Professor Tom Strachan
et al.
Breakpoint position on 17q identifies the most aggressive neuroblastoma tumors2002
Dr Brian Angus
Professor John Lunec
Dr Stephen Crosier
Andrew Lodge
Dr John Anderson
et al.
Comparative assessment expression of the inhibitor of growth 1 gene (ING1) in normal and neoplastic tissues2002
Nidal Boulos
Professor Andrew Pearson
Dr Michael Tilby
Professor John Lunec
Functional complementation analysis of chromosome 1 in neuroblastoma2002
Professor John Lunec
Professor Alan Calvert
Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism2002
Dr John Anderson
Dr Katrina Wood
Professor John Lunec
Dr Andrew Hall
Dr Michael Reid
et al.
Loss of nuclear expression of the p33ING1b inhibitor of growth protein in childhood acute lymphoblastic leukaemia2002
Dr John Anderson
Dr Marie Mathers
Dr Niamh Leonard
Dr Stephen Crosier
Professor John Lunec
et al.
Nuclear to cytoplasmic compartment shift of the p33ING1b tumour suppressor protein is associated with malignancy in melanocytic lesions2002
Seamus Kelly
Dr John Anderson
Dr Brian Angus
Professor John Lunec
p33/ING1 nuclear expression and TP53 gene mutation in colorectal cancer and their association with clinical outcome2002
Dr John Anderson
Dr Stephen Crosier
Dr Jyotsna Shrimankar
Professor John Lunec
Dr Brian Angus
et al.
p33ING1b tumour suppressor immunohistochemical expression in invasive breast carcinomas2002
Professor John Lunec
Julian Board
Professor Andrew Pearson
Quantification of MYCN, DDX1, and NAG gene copy number in neuroblastoma using a real-time quantitative PCR assay2002
Alice Burns
Dr Evelyn Jaros
Mike Cole
Emeritus Professor Robert Perry
Professor Andrew Pearson
et al.
The molecular pathology of p53 in primitive neuroectodermal tumours of the central nervous system2002
Seamus Kelly
Dr John Anderson
Dr Brian Angus
Professor John Lunec
TP53 and p33(Ing1) are co-determinants of prognosis in colorectal cancer2002
Dr Xiaomei Lu
Julie Errington
Professor Nicola Curtin
Professor John Lunec
Professor Herbie Newell
et al.

The impact of p53 status on cellular sensitivity to antifolate drugs

2001
Dr Richard Gilbertson
Roberto Hernan
Emeritus Professor Robert Perry
Professor John Lunec
Professor Andrew Pearson
et al.
Clinical and molecular stratification of disease risk in medulloblastoma2001
Dr Khaver Qureshi
Thomas Griffiths
Dr Mary Robinson
Colin Marsh
Dr James Roberts
et al.
Combined p21WAF1/CIP1 and p53 overexpression predict improved survival in muscle-invasive bladder cancer treated by radical radiotherapy2001
Dr Brian Angus
Professor David Neal
Professor John Lunec
Kilian Mellon
Cyclin D1 expression in transitional cell carcinoma of the bladder: Correlation with p53, waf1, pRb and Ki672001
Professor Deborah Tweddle
Professor Archibald Malcolm
Dr Nicholas Bown
Professor Andrew Pearson
Professor John Lunec
et al.
Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line2001
Professor John Lunec
Seamus Kelly
Dr John Anderson
Dr Brian Angus
Expression of p33/ING1 gene products in colorectal cancer and its correlation with survival2001
Dr Debbie Scott
Professor Andrew Pearson
Professor John Lunec
Identification of novel coding exons within the neuroblastoma amplified gene, NAG.2001
Professor Alan Calvert
Professor Nicola Curtin
Emeritus Professor Bernard Golding
Professor Roger Griffin
Dr Ian Hardcastle
et al.
Inhibiting the MDM2-p53 interaction using low molecular weight compounds2001
Joanna Elsden
Dr Rebecca Kenyon
Professor Andrew Pearson
Professor John Lunec
Is DDX1 an oncogene? How does its pattern of expression relate to its amplification status?2001
Dr Maria Lastowska
Dr Nicholas Bown
Professor John Lunec
Professor Tom Strachan
Professor Andrew Pearson
et al.
Molecular cytogenetic definition of 17q translocation breakpoints in neuroblastoma2001
Dr Maria Lastowska
Dr Nicholas Bown
Professor John Lunec
Professor Tom Strachan
Professor Andrew Pearson
et al.
Molecular cytogenetic definition of 17q translocation breakpoints in neuroblastoma2001
Dr Richard Gilbertson
Roberto Hernan
Professor David Ellison
Emeritus Professor Robert Perry
Professor Andrew Pearson
et al.
Novel ErbB4 juxtamembrane splice variants and the truncated ErbB2 receptor isoform are frequently expressed in childhood medulloblastoma2001
Dr Richard Gilbertson
Roberto Hernan
Professor David Ellison
Emeritus Professor Robert Perry
Professor Andrew Pearson
et al.
Novel ERBB4 juxtamembrane splice variants are frequently expressed in childhood medulloblastoma2001
Dr John Anderson
Professor John Lunec
Dr Andrew Hall
Dr Michael Reid
Dr Brian Angus
et al.
p33(ING1b) tumour suppresser protein expression in childhood acute lymphoblastic leukaemia by immunohistochemistry2001
Dr Stephen Crosier
Dr John Anderson
Dr Marie Mathers
Dr Niamh Leonard
Dr Stephen Crosier
et al.
p33(ING1b) tumour suppresser protein expression in melanocytic lesions, an immunohistochemical study of 67 cases2001
Seamus Kelly
Professor John Lunec
Dr John Anderson
Dr Brian Angus
p33/ING1 nuclear expression in colorectal cancer and its correlation with metastasis and survival2001
Dr John Anderson
Dr Stephen Crosier
Professor John Lunec
Dr Brian Angus
p33ING1b tumour suppresser protein expression in thyroid lesions determined by immunohistochemistry2001
Professor Deborah Tweddle
Professor Archibald Malcolm
Mike Cole
Professor Andrew Pearson
Professor John Lunec
et al.
p53 cellular localization and function in neuroblastoma: evidence for defective G1 arrest despite WAF1 induction in MYCN-amplified cells2001
Garrett Durkan
Dr Joyce Nutt
Professor David Neal
Professor John Lunec
Kilian Mellon
et al.
Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder2001
Simon Cotterill
Professor John Lunec
Professor Andrew Pearson
Relationship between histopathological features, MYCN amplification, and prognosis: A UKCCSG study2001
Dr Paul Jowsey
Gillian Farnie
Professor barbara Durkacz
Professor John Lunec
The dependence of p63 induction and activity on poly (ADP-ribose) polymerase-12001
Professor Andrew Pearson
Emeritus Professor Robert Perry
Professor John Lunec
Detection of amplified and transcribed sequences at the chromosome 12q13-15 locus in NGP neuroblastoma cells by Alu-PCR2000
Professor John Lunec
Vanessa Ashton
Jennifer Wilson
Expression of cyclin-dependent kinase inhibitor p21((WAF1)) and p53 tumour suppressor gene in laryngeal cancer2000
Dr Nicholas Bown
Professor John Lunec
Professor Archibald Malcolm
Professor Andrew Pearson
Fluorescence in situ hybridization techniques for the rapid detection of genetic prognostic factors in neuroblastoma2000
Dr Brian Angus
Professor John Lunec
Dr John Anderson
Monoclonal antibodies raised to products of the ING1 tumour suppressor gene locus.2000
Dr John Anderson
Dr Brian Angus
Professor John Lunec
Sequencing of ING1 tumour suppressor gene cDNAs generated from mRNA recovered from normal and neoplastic cell lines.2000
Philip Keegan
Professor John Matthews
Professor John Lunec
Professor David Neal
Statistical problems with 'optimal' thresholds in studies of new prognostic factors in urology2000
Dr Brian Angus
Dr Sathyarathna Gokul
Professor Alan Calvert
Professor John Lunec
Bcl-2 expression is a potential prognostic co-factor with P53- mutation status in epithelial ovarian carcinoma1999
Dr Catherine Bladen
Professor John Lunec
Can the acidic domain of the MDM2 oncoprotein act as a transcriptional transactivation domain?1999
Professor Alan Calvert
Dr Martin Highley
Professor John Lunec
Professor Alan Boddy
Carboplatin and paclitaxel, alone and in combination: Dose escalation, measurement of renal function, and role of the p53 tumor suppressor gene1999
Dr Richard Gilbertson
Roberto Hernan
Professor Andrew Pearson
Professor John Lunec
Expression and characterisation of novel ErbB-4 alternative spliced variants by childhood1999
Gordon Taylor
Professor John Lunec
Professor Andrew Pearson
Professor Herbie Newell
Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines1999
Dr Joyce Nutt
Garrett Durkan
Professor John Lunec
Matrixmetalloproteinase stimulation in bladder tumour cell lines and elevated levels in the urine of bladder tumour patients.1999
Philip Keegan
Professor John Lunec
Professor David Neal
p53 and p53-regulated genes in bladder cancer - Reply1999
Philip Keegan
Professor John Matthews
Professor John Lunec
Professor David Neal
Statistical problems with "optimal' cut-points in studies of new prognostic factors in urology.1999
Dr Richard Gilbertson
Roberto Hernan
Professor Andrew Pearson
Professor John Lunec
The ErbB2 receptor represents a potential target for novel therapies in childhood medulloblastoma.1999
Dr Khaver Qureshi
Thomas Griffiths
Dr Mary Robinson
Dr James Roberts
Professor John Lunec
et al.
TP53 accumulation predicts improved survival in patients resistant to systemic cisplatin-based chemotherapy for muscle-invasive bladder cancer1999
Professor John Lunec
A novel p53 binding sequence in intron 3 of the human MDM2 proto-oncogene: A putative additional p53-dependent promoter1998
Dr Christine Challen
Thomas Griffiths
Dr Mary Robinson
Professor David Neal
Professor John Lunec
et al.
Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: High frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis1998
Dr Khaver Qureshi
Thomas Griffiths
Dr Mary Robinson
Reginald Hall
Professor John Lunec
et al.
Chemotherapy and muscle-invasive bladder cancer: Assessment of p53 immuno-reactivity (IR) as a predictor of response1998
Dr Brian Angus
Professor David Neal
Professor John Lunec
Kilian Mellon
Cyclin Dl expression in TCC of the bladder: Correlation with WAF1, p53 and Ki671998
Dr Catherine Bladen
Professor John Lunec
Does the acidic domain of the MDM2 oncoprotein have a transcriptional control function?1998
Professor Deborah Tweddle
Professor Andrew Pearson
Professor Archibald Malcolm
Professor John Lunec
Does TP53 function in neuroblastoma?1998
Dr Wendy Scaife
Professor David Neal
Professor John Lunec
Evaluation of the yeast functional (FASAY) assay for detecting p53 mutations in bladder cancers1998
Professor John Lunec
Emerita Professor Janet Wilson
Dr Charles Kelly
Expression of cyclin dependent kinase inhibitors in laryngeal cancer1998
Alice Burns
Dr Evelyn Jaros
Professor Andrew Pearson
Emeritus Professor Robert Perry
Professor John Lunec
et al.
Expression of p53, Waf-1, Bcl-2, and Bax in central primitive neuroectodermal tumours (cPNET)1998
Dr Richard Gilbertson
Professor Steven Clifford
Dr Christopher Wright
Emeritus Professor Robert Perry
Professor Andrew Pearson
et al.
Expression of the ErbB-neuregulin signaling network during human cerebellar development: Implications for the biology of medulloblastoma1998
Professor John Lunec
Genomic mapping of the human MDM2 oncogene and the relationship between exon/intron boundaries and variant MDM2 transcripts1998
Dr Joyce Nutt
Kilian Mellon
Dr Khaver Qureshi
Professor John Lunec
Matrix metalloproteinase-1 is induced by epidermal growth factor in human bladder tumour cell lines and is detectable in urine of patients with bladder tumours1998
Dr Khaver Qureshi
Professor John Lunec
Professor David Neal
Molecular biological changes in bladder cancer1998
Dr Maria Lastowska
Dr Nicholas Bown
Professor John Lunec
Professor Tom Strachan
Professor Andrew Pearson
et al.
Molecular cytogenetic delineation of 17q translocation breakpoints in neuroblastoma cell lines1998
Simon Cotterill
Professor John Lunec
Professor Andrew Pearson
Neuroblastoma cells provoke Schwann cell proliferation in vitro1998
Philip Keegan
Professor John Lunec
Professor David Neal
p53 and p53-regulated genes in bladder cancer1998
Dr Andrew Hall
Professor John Lunec
Professor Herbie Newell
Professor Andrew Pearson
Geoffrey Taylor
et al.
Thymidylate synthase expression in nolatrexed and methotrexate-resistant human leukaemia cell lines1998
Professor Deborah Tweddle
Professor Archibald Malcolm
Dr Michael Reid
Mike Cole
Professor John Lunec
et al.
TP53 and related protein expression in primary and metastatic neuroblastoma1998
Dr Rebecca Kenyon
Professor Andrew Pearson
Professor John Lunec
Analysis of candidate gene co-amplification with MYCN in neuroblastoma1997
Dr Richard Gilbertson
Dr Evelyn Jaros
Emeritus Professor Robert Perry
Professor John Lunec
Professor Andrew Pearson
et al.
Mitotic percentage index: A new prognostic factor for childhood medulloblastoma1997
Dr Richard Gilbertson
Emeritus Professor Robert Perry
Professor Andrew Pearson
Professor John Lunec
Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma1997
Dr Richard Gilbertson
Dr Evelyn Jaros
Professor John Lunec
Professor Andrew Pearson
The epidermal growth factor receptor (EGFR) family and childhood medulloblastoma1997
Professor Alan Calvert
Dr Andrew Hall
Professor John Lunec
Professor Herbie Newell
Professor Andrew Pearson
et al.
The relationship between intrinsic thymidylate synthase expression and sensitivity to THYMITAQ® in human leukaemia and colorectal carcinoma cell lines1997
Professor Steven Clifford
Professor David Neal
Professor John Lunec
Alterations in expression of the multidrug resistance-associated protein (MRP) gene in high-grade transitional cell carcinoma of the bladder1996
Professor Alan Calvert
Dr John Anderson
Professor David Neal
Professor John Lunec
Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: Transforming ability and frequent detection in human cancer1996
Kilian Mellon
Professor John Lunec
Dr Christopher Wright
Professor David Neal
C-erbB-2 in bladder cancer: Molecular biology, correlation with epidermal growth factor receptors and prognostic value1996
Professor Steven Clifford
Professor David Neal
Professor John Lunec
High level expression of the multidrug resistance (MDR1) gene in the normal bladder urothelium: A potential involvement in protection against carcinogens?1996
Dr Joyce Nutt
Professor John Lunec
Induction of metalloproteinase (MMP1) expression by epidermal growth factor (EGF) receptor stimulation and serum deprivation in human breast tumour cells1996
Professor John Lunec
Interruption of binding of MDM-2 and p53 protein; potential for the treatment of cancer 1996
Dr Rebecca Kenyon
Professor Archibald Malcolm
Professor Andrew Pearson
Professor John Lunec
Investigation of co-amplification of the candidate genes ornithine decarboxylase, ribonucleotide reductase, syndecan-1 and a DEAD box gene, DDX1, with N-myc in neuroblastoma1996
Dr Evelyn Jaros
Professor John Lunec
P53 overexpression in head and neck carcinoma and radiotherapy results1996
Dr Evelyn Jaros
Professor John Lunec
P53 overexpression in head and neck carcinoma and radiotherapy results1996
Professor David Ellison
Professor John Lunec
Dr Evelyn Jaros
Accumulation of wild-type p53 in meningiomas1995
Professor Alan Calvert
Professor John Lunec
Molecular characterisation of 2 cell-lines selected for resistance to the folate-based thymidylate synthase inhibitor, ZD16941995
Professor John Lunec

A novel family of cathespin L-like (CTSLL) sequences on human-chromosome 10Q and related transcripts

1994
Professor John Lunec
Carole Todd
Professor Anthony Thody

Cultured Human Melanocytes Respond to MSH Peptides and ACTH

1994
Professor David Neal
Professor John Lunec

FREQUENCY OF H-RAS MUTATIONS IN HUMAN BLADDER-CANCER DETECTED BY DIRECT SEQUENCING

Frequency of H-ras mutations in human bladder cancer detected by direct sequencing

1994
Professor Steven Clifford
David Thomas
Professor David Neal
Professor John Lunec

Increased MDR1 gene transcript levels in high-grade carcinoma of the bladder determined by quantitative PCR-based assay

1994
Professor John Lunec
Professor Anthony Thody

MSH Receptors and Function in Amelanotic B16 Melanoma-Cells

1993
Dr Evelyn Jaros
Professor John Lunec
Emeritus Professor Robert Perry
Professor Andrew Pearson

P53 Protein Overexpression Identifies a Group of Central Primitive Neuroectodermal Tumors with Poor Prognosis

1993
Professor John Lunec
Dr Gajanan Sherbet
DNA Repair and Repair Fidelity in Metastatic Variants of the B16 Murine Melanoma1993
Professor John Lunec

Analysis of the P54 tumor-suppressor gene in hepatocellular carcinomas from Britain

1992
Professor John Lunec
Professor Anthony Thody

Demonstration of specific melanocyte stimulating hormone receptors on human melanocytes grown in a system free of artificial mitogens

1992
Professor barbara Durkacz
Professor John Lunec
Professor Michael Griffin

Murine Melanoma Cell-Differentiation and Melanogenesis Induced by Poly(ADP-Ribose) Polymerase Inhibitors

1992
Dr Christine Challen
Professor John Lunec
Professor Margaret Bassendine
Analysis of the p53 tumour suppressor gene in HCCs from Britain.1992
Professor John Lunec
Dr Christine Challen
Dr Christopher Wright
Professor David Neal
c-erbB-2 amplification and identical p53 mutations in concomitant transitional carcinomas of renal pelvis and urinary bladder1992
Professor John Lunec
Professor Alan Calvert
Human Lymphoblastoid-Cells with Acquired-Resistance to C2- Desamino-C2-Methyl-N10-Propargyl-5,8-Dideazafolic Acid - a Novel Folate-Based Thymidylate Synthase Inhibitor1992
Professor John Lunec
Professor Anthony Thody
MSH receptor expression and the relationship to melanogenesis and metastatic activity in B16 melanoma 1992
Professor John Lunec
Professor Anthony Thody
The expression of functional MSH receptors on cultured human melanocytes1992
Dr Christopher Wright
Professor John Lunec
Professor David Neal

P53, C-ERB-2 and EGFR in bladder cancer

1991
Dr Joyce Nutt
Professor John Lunec

Phorbal ester and bryostatin effects on growth and the expression of estrogen and TGF-beta in breast-tumor cells

1991
Professor John Lunec
Professor Margaret Bassendine
P53 - A frequent target for genetic abnormalities in human hetatocellular carcinomas (HCCS) in Britain1991
Dr Joyce Nutt
Professor John Lunec

Effects of estradiol, TPA and bryostatin on growth, the transcriptional regulation of estrogen responsive genes and the expression of TGF-beta in human breast tumor-lines

1990
Dr Joyce Nutt
Professor John Lunec

Interactive effects of estradiol, TPA and bryostatin on growth and on the expression of estrogen responsive genes and TGF-beta in human breast tumor lines

1990
Professor John Lunec
Dr Gajanan Sherbet
Professor Anthony Thody
Alpha-melanocyte-stimulating hormone immunoreactivity in melanoma-cells1990
Dr Gajanan Sherbet
Professor John Lunec
DNA-Repair Fidelity and Recombination Proficiency in B16 Melanoma Metastatic Variants1989
Professor John Lunec
Dr Craig Parker
Dr Gajanan Sherbet
Epidermal growth-factor receptor expression in primary breast-tumor tissue1989
Professor John Lunec
Dr Gajanan Sherbet
Professor Anthony Thody
Pigment-cells are able to synthesize MSH peptides1988
Professor John Lunec
Dr Craig Parker
Dr Gajanan Sherbet
Professor Anthony Thody
Possible Autocrine Control of Growth and Progression of Melanonma by Alpha-MSH1988
Professor John Lunec
Dr Craig Parker
Dr Gajanan Sherbet
The isolation of CDNA clones for cysteine proteases and measurement of the expression of corresponding genes in metastatic variants of B-16 melanoma1988
Dr Gajanan Sherbet
Dr Madurai Lakshmi
Professor John Lunec
Dr Craig Parker
The generation of metastatic mosaicism in B-16 murine melanoma1987